

DETECTION OF HEPATITIS A ANTIBODIES BY ELISA USING SALIVA AS CLINICAL SAMPLES

Isabel Takano OBA(1), Angela Maria Miranda SPINA(1), Cláudia Patara SARACENI(1), Márcilio Figueiredo LEMOS(1), Rita de Cássia Ferreira Andrade SENHORAS(2), Regina Célia MOREIRA(1) & Celso Francisco Hernandes GRANATO(3)

SUMMARY

The possibility of detecting acute infection and immunity using body fluids that are easier to collect than blood, mainly in children, would facilitate the investigation and follow-up of outbreaks of hepatitis A (HAV). Our study was carried out to evaluate the detection of anti-HAV IgM, IgA and total antibodies in saliva using serum samples as reference. Forty three paired serum and saliva samples were analyzed. From this total, 24 samples were obtained from children and 1 from one adult during the course of acute hepatitis A; an additional 18 samples were obtained from health professionals from Adolfo Lutz Institute. The sensitivity to detect anti-HAV IgM was 100% (95%CI: 79.1 to 100.0%), employing saliva as clinical samples. In detecting anti-HAV IgA, the sensitivity was 80.8% (95%CI: 60.0 to 92.7%) and for the total antibodies was 82.1% (95%CI: 62.4 to 93.2%). The specificity was 100% for each. The rate of agreement was high comparing the results of serum and saliva samples for detecting HAV antibodies. We conclude that saliva is an acceptable alternative specimen for diagnosing acute hepatitis A infection, and for screening individuals to receive hepatitis A vaccine or immunoglobulin.

KEYWORDS: Hepatitis A; Saliva; Antibodies; Vaccine

INTRODUCTION

Hepatitis A is one of the most common causes of infectious hepatitis in the World and the major means of transmission include contamination of water supply and food. It is caused by a virus that belongs to the *Picornaviridae* family, genus *Hepatovirus*, HAV (HOLLINGER & TICEHURST, 1996; KOFF, 1998).

Brazil is a country with a suboptimal network of public sanitation. The prevalence of anti-HAV IgG antibody is high, reaching about 90% of children by ten years of age (CARRILHO & SILVA, 1995). This epidemiological profile could be changing, at least in certain social groups, according to PINHO *et al.* (1998), who carried out a seroepidemiological study on university students from a high social-economic level, and found within that population only 19.6% were anti-HAV positive. Clinically, hepatitis A follows an anicteric or completely asymptomatic course in 95% of children, up to five years of age (ROSS *et al.*, 1991). In adults the disease is more severe and prolonged (LEDNAR *et al.*, 1985; ZACHOVAL & DEINHARDT, 1998), but does not lead to a chronic carrier state (BATTEGAY *et al.*, 1995).

An initial serological response against HAV is directly related to the humoral immunity, given the formation of IgM, IgG and IgA antibodies,

which are detectable at the onset of symptoms (ROSS *et al.*, 1991; LEMON, 1985).

The anti-HAV IgM antibody is transient, generally persisting for six to eight months after the acute infection. Its detection is therefore indicative of recent infection by HAV (KOFF, 1992; LEMON & STAPLETON, 1998; LOCARNINI *et al.*, 1979).

The anti-HAV IgG antibody increases gradually, reaching high levels during the convalescent phase (STAPLETON *et al.*, 1991) and remains for life, conferring immunity against reinfection.

Secretory IgA is associated with intestinal resistance to many viral infections, as is the case of the Polioviruses. The oral vaccine, obtained from attenuated viral strains, induces the production of this antibody and protects against enteric reinfection. In spite of this, some authors have shown that in case of infection by HAV, intestinal immunity does not represent protection against this virus (STAPLETON, 1995).

Laboratory diagnosis in cases of Hepatitis A is established by measuring in the serum the levels of intracellular hepatic enzymes (ALT and AST) as well as by the detection of anti-HAV IgM antibodies in blood samples (HESS *et al.*, 1995).

(1) Department of Virology, Instituto Adolfo Lutz, SP, Brazil.

(2) Health Center, São Sebastião da Gramma, SP, Brazil.

(3) Department of Virology, School of Medicine, Federal University of São Paulo, SP, Brazil.

Correspondence to: Isabel Takano Oba, Serviço de Virologia, Laboratório de Hepatites, Instituto Adolfo Lutz, Av. Dr. Arnaldo 355, 01246-902 São Paulo, SP, Brazil. E-mail: isabeltoba@hotmail.com

The difficulty in collecting blood samples, mainly in children, and the ease and reliability of the collection of saliva samples have led various authors to develop methods, or adapt already existing techniques, for the detection of specific antibodies found in saliva (PARRY *et al.*, 1987) and in urine (PARRY, 1993).

During outbreaks of Hepatitis A, collection of blood samples is usually necessary for serological testing and establishment of etiological diagnosis. This diagnosis allows the determination of measures for prevention and control of the disease. The general acceptance of collecting saliva samples is far greater in the entire community and this would greatly facilitate investigations and follow-up of outbreaks (PARRY, 1993). Saliva samples are less expensive to collect when compared to blood samples.

The detection of antibodies in saliva was initially demonstrated by ARCHIBALD *et al.* (1986). Since then, various studies were undertaken, utilizing saliva samples not only for the diagnosis of recent and past infection, but for evaluation of the response of the Hepatitis A vaccine (LAUFER *et al.*, 1995; OCHNUI *et al.*, 1997; PARRY *et al.*, 1987; PARRY *et al.*, 1989; PARRY, 1993; PIACENTINI *et al.*, 1993; THIEME *et al.*, 1992).

The advantage of utilizing saliva in tests for the diagnosis of Hepatitis A is the ease of collection, making this a satisfactory and convenient alternative (PARRY *et al.*, 1989), especially if we consider that in this epidemiological setting the majority of the patients are children.

In the present study, we compared results obtained by the detection of antibodies of the IgM, IgA and IgG class against HAV, in both saliva and serum samples. We evaluated the possibility of replacing serum by saliva samples for diagnosis and for selection of candidates for vaccination against Hepatitis A.

MATERIAL AND METHODS

Forty-three paired serum and saliva samples were analyzed. Twenty-four of them were obtained from children involved in an outbreak of hepatitis A which occurred in the country of São Sebastião da Gramma, São Paulo State, Brazil. One set of samples came from an adult with acute hepatitis A and 18 other set of samples were provided by employees from the Instituto Adolfo Lutz, apparently healthy and without clinical or epidemiological risks of hepatitis.

Blood samples were subjected to centrifugation and serum was separated and transferred to previously labelled 5 mL test tubes. Saliva samples were obtained by utilizing Omni-SAL saliva collectors (Saliva Diagnostic Systems, Singapore) and refrigerated at -20°C until the moment of testing. They were tested diluted 1:5, in phosphate buffered saline (pH 7.4) with 1% bovine serum albumine (PBS-A). Serum samples and the results obtained with them were used as reference samples, while the saliva samples were utilized as alternatives.

The presence of anti-HAV antibodies of IgG, IgM and IgA classes were assayed in both serum and saliva samples. In saliva samples, IgG as well as IgM antibodies were detected by adaptations of commercial enzyme immunoassays (SORIN[®] ETI-AB-HAVK-2, ETI-AB-HAVK-3 and ETI-HA-IgMK-2). Serum samples were substituted by saliva in the

first incubation period. The tests on serum were performed according to the instructions of the producer.

For the experiments to detect IgA class antibody, the samples were analyzed using SORIN[®] ETI-AB-HAVK-3 kits, with some modifications.

According to the procedures described by CROWTHER (1995), polystyrene microplates were coated with 100 μL of the goat anti-human IgA antibody (SIGMA), diluted at 1:800 in 50 mM carbonate-bicarbonate buffer (pH 9.6). After a 16 hours incubation, blocking was achieved with 100 μL of PBS-A. One hundred microliters of dilution of saliva samples in PBS-A 1:5 was added and incubated at 4°C for 18 to 20 hours. After this period, the microplate was washed four times with a PBS/Tween (0.5 %) solution and 100 μL of HAV antigen provided by the commercial kit were added, and incubated at 37°C for 2 hours. Following this incubation and after washing the microplate wells, 100 μL conjugate were added (human antibody anti-HAV conjugated with peroxidase, a reagent included in the SORIN[®]-ETI-AB-HAVK-3 kit). The final step of the reaction was the addition to each well of 100 μL of a substrate solution containing tetrametilbenzidine and hydrogen peroxide buffered citrate. The microplate was incubated at room temperature for 30 minutes, protected from light, and the reaction was later interrupted by the addition of 100 μL of sulfuric acid (1N) to each well. The reading of the reaction was done using a microplate spectrophotometer (Microwell System Reader 510 - Organon Teknika[®], filter 492nm and 600nm) and the cut-off of the reaction was determined by calculating the mean optical density (OD) of four known negative samples and adding three standard deviations. Samples which showed an OD above the cut-off value were considered positive.

Positive and negative controls were included in all experiments.

In order to assess the statistical significance of the association, 95% confidence intervals (CI) were used.

RESULTS

Detection of total anti-HAV in saliva samples. Of the 43 paired serum and saliva samples 28 were collected from serologically positive subjects. A positive result was observed in 23/28, oral fluid specimens, showing a sensitivity of 82.1% (95%CI: 62.4 to 93.2%); 15 subjects were negative for serum as well as saliva, resulting in a specificity of 100% (95%CI: 74.7 to 100.0%). The agreement between the results of the two clinical samples was 88.4%.

Detection of anti-HAV antibodies of the IgA class in saliva samples. Of the 43 subjects 26 had detectable IgA anti-HAV in their serum, of which 21 were also positive for this marker in saliva, representing a sensitivity of 80.8% (95%CI: 60.0 to 92.7%) in both clinical samples. Seventeen matched serum and saliva samples were negative for this marker, resulting in a specificity of 100% (95%CI: 77.1 to 100.0%). The agreement between the results was 88.4 %.

Detection of anti-HAV antibodies of the IgM class in saliva samples. Of the 43 matched sample sets analyzed, 19 were positive for IgM antibodies while 24 were negative for this marker. We observed complete agreement for the detection of the anti-HAV of the IgM class, utilizing the same methodology but different clinical samples (serum

and saliva), representing a sensitivity of 100.0% (95%CI: 79.1 to 100.0%) and specificity of 100.0% (95%CI: 82.8 to 100.0%).

DISCUSSION

Hepatitis caused by HAV can not be differentiated from other etiologies, based only upon the clinical and epidemiologic characteristics. The serum test for the detection of anti-HAV IgM is necessary to confirm the etiologic diagnosis of the acute infection, while the detection of IgG antibodies indicates immunity and long-lasting protection against the virus. In the epidemiological setting found in Brazil, the finding of IgG anti-HAV rarely can be used to clarify the diagnosis. For routine laboratory diagnosis of acute Hepatitis A, commercially available immunoenzymatic tests were used, employing sera as clinical samples.

Similarly our results demonstrate that saliva can be utilized in tests for the detection of total antibodies against HAV, and that this strategy could be applicable to screening vaccine candidates or candidates for gammaglobulin injections, with a reasonable degree of confidence, as we obtained a sensitivity of 82.1% and a specificity of 100% for this marker.

STAPLETON (1995) and STAPLETON *et al.* (1991) have demonstrated, by means of radioimmunoassay, the presence of anti-HAV IgA, in 9 out of 14 saliva samples obtained from individuals during an outbreak of Hepatitis A, 56 days after the onset of jaundice.

The detection of anti-HAV IgA in saliva and serum samples in our study presented a sensitivity of 80.8% and a specificity of 100%. Furthermore, an agreement of 88.4% between both types of samples, serum and saliva, was obtained. We observed that anti-HAV IgA antibodies in saliva and serum are slightly less detectable than the anti-HAV IgG (21 and 23 out of 43 versus 23 and 26 out of 43).

LAUFER *et al.* (1995) analyzed the presence of IgG in saliva in vaccinated individuals as well as in non-vaccinated people. They observed 100% of agreement in the detection of IgG acquired after natural infection, while concordance among the vaccinated individuals was only 28%. This fact can be explained by the difference in the levels of antibodies which were naturally produced as opposed to the ones acquired by active immunization. In our study, we do not evaluate the response to vaccination against Hepatitis A.

In relation to the detection of IgM, PARRY (1993) and PARRY *et al.* (1987, 1989) using the competition radioimmunoassay, demonstrated that anti-HAV IgM can be reliably detected in the saliva of patients with acute or recently acquired Hepatitis A. Fourteen serum and saliva samples with recent hepatitis, collected simultaneously, were tested for anti-HAV IgM. Eight cases were confirmed as acute Hepatitis A by serum examination. The reactivity in serum was very similar to the one found in saliva. These authors observed that anti-HAV IgM in saliva samples can be detected, in moderate levels, from two to four months after the onset of symptoms. After this period, detection became practically impossible.

Similarly, PIACENTINI *et al.* (1993), obtained a sensitivity of 100% and a specificity of 98% in anti-HAV IgM detection tests in paired serum and saliva samples.

In our study, anti-HAV IgM was detected in 19 simultaneously collected serum and saliva samples, showing a concordance of 100%.

Altogether these data suggest the possibility of substitution of serum by saliva as clinical samples for the diagnosis of acute Hepatitis A.

BULL *et al.* (1989), studying an outbreak of Hepatitis A in a school, utilized saliva samples to carry out an epidemiologic investigation. Two samples were collected from the entire school community at an interval of ten weeks. In four individuals with acute Hepatitis A anti-HAV IgM was detected. It persisted in the saliva for two to three months after initiation of the clinical signs (jaundice), confirming the results that PARRY *et al.* (1989) carried out at the same time.

THIEME *et al.* (1992) addressed the issue of the longevity of antibody detection. The detection of anti-HAV IgM in saliva and serum samples showed 100% sensitivity and 98% specificity. In the longitudinal study of HAV in 5 patients, the IgM antibody decline in saliva and serum samples was similar for both, though two patients showed a decline in saliva samples before they did in serum samples. This decline could have occurred due to the low sensitivity of the saliva test in relation to the serum test or to the degradation of the antibodies by the salivary enzymes. Anti-HAV IgM was detected in the saliva for 60 days and the total anti-HAV (IgM and IgG) was detected for more than 320 days after the onset of symptoms. The authors demonstrated that saliva can be utilized as clinical samples for the diagnosis of acute infection and monitoring of immunization against HAV.

Our study demonstrates and confirms the possibility of substitution of serum by saliva in laboratory diagnosis of hepatitis A and in the selection of individual candidates for active or passive immunization.

RESUMO

Detecção de anticorpos anti-VHA em amostras de saliva utilizando teste imuno-enzimático

A possibilidade de identificar infecções presentes ou passadas utilizando fluidos corpóreos que seriam mais facilmente coletados do que o sangue, principalmente em crianças, facilitaria grandemente a investigação e o acompanhamento de surtos de hepatite A, que ocorrem com muita frequência em nosso meio.

Nosso estudo foi desenvolvido com a finalidade de avaliar a detecção dos anticorpos anti-VHA, da classe IgA, IgM, e anticorpos totais em amostras de saliva, usando amostras de soro como padrão.

Foram estudadas 43 amostras pareadas de saliva e de soro, colhidas de 24 crianças e de um adulto durante um surto de hepatite A, e de 18 funcionários do Instituto Adolfo Lutz.

Empregando saliva como amostra clínica, a sensibilidade para a detecção de anti-VHA IgM foi de 100,0%, de anti-VHA IgA foi de 80,8% e de anti-VHA total foi de 82,1%. Não houve nenhum resultado falso-positivo, sendo a especificidade de 100%.

A concordância foi alta entre os resultados das amostras de saliva e soro na detecção dos anticorpos, indicando que amostras de saliva podem

ser utilizadas no diagnóstico de infecção aguda pelo VHA e na seleção de indivíduos para vacinação contra o VHA, para conter surtos.

REFERENCES

1. ARCHIBALD, D.W.; ZON, L.I.; GROOPMAN, J.E. *et al.* - Salivary antibodies as a means of detecting human T cell lymphotropic virus type III/ lymphadenopathy-associated virus infection. *J. clin. Microbiol.*, **24**: 873-875, 1986.
2. BATTEGAY, M.; GUST, I.D. & FEINSTONE, S.M. - Hepatitis A virus. In: MANDELL, G.L.; BENNETT, J. & DOLIN, R., ed. **Principles and practice of infectious diseases**. 4. ed. Edinburgh, Churchill Livingstone, 1995. p. 1636-1656.
3. BULL, A.R.; KIMMANCE, K.J.; PARRY, J.V. & PERRY, K.R. - Investigation of an outbreak of hepatitis A simplified by salivary antibody testing. *Epidem. Infect.*, **103**: 371-376, 1989.
4. CARRILHO, F.J. & SILVA, L.C. - Epidemiologia. In: SILVA, L.C. da, ed. **Hepatites agudas e crônicas**. 2. ed. São Paulo, Sarvier, 1995. p. 73-87.
5. CROWTHER, J.R. - Stages in ELISA. In: CROWTHER, J.R. **ELISA: theory and practice**. New Jersey, Humana Press, 1995. p. 63-97.
6. HESS, G.; FAATZ, E.; MELCHIOR, W. & BAYER, H. - Analysis of immunoassays to detect antibodies to hepatitis A virus (anti-HAV) and anti-HAV immunoglobulin M. *J. virol. Meth.*, **51**: 221-228, 1995.
7. HOLLINGER, F.B. & TICEHURST, J.R. - Hepatitis A. In: FIELDS, B.N.; KNIPE, D.M. & HOWLEY, P.M., ed. **Virology**. Philadelphia, Raven Press, 1996. p. 735-781.
8. KOFF, R.S. - Clinical manifestation and diagnosis of hepatitis A virus infection. *Vaccine*, **10**: S15-S17, 1992.
9. KOFF, R.S. - Hepatitis A. *Lancet*, **351**: 1643-1649, 1998.
10. LAUFER, D.S.; HURNI, W.; WATSON, B. *et al.* - Saliva and serum as diagnostic media for antibody to hepatitis A virus in adults and in individuals who have received an inactivated hepatitis A vaccine. *Clin. infect. Dis.*, **20**: 868-871, 1995.
11. LEDNAR, M.W.; LEMON, M.S. & KIRKPATRICK, W.J. - Frequency of illness associated with epidemic hepatitis A virus infections in adults. *Amer. J. Epidem.*, **122**: 226-233, 1985.
12. LEMON, M.S. - Type A viral hepatitis: new developments in an old disease medical progress. *New Engl. J. Med.*, **313**: 1059-1066, 1985.
13. LEMON, S.M. & STAPLETON, J.T. - Prevention. In: ZUCKERMAN, A.J. & THOMAS, H.C., ed. **Viral hepatitis: scientific basis and clinical management**. Edinburgh, Churchill Livingstone, 1998. p. 63-76.
14. LOCARNINI, A.S.; COULEPIS, G.A.; STRATTON, M.A.; KALDOR, J. & GUST, D.I. - Solid-phase enzyme-linked immunosorbent assay for detection of hepatitis A-specific immunoglobulin M. *J. clin. Microbiol.*, **9**: 459-465, 1979.
15. OCHNUI, J.J.; SCHEIFELE, D.W.; HO, M. & MITCHELL, L.E.A. - New, ultrasensitive enzyme immunoassay for detecting vaccine and-disease-induced hepatitis A virus-specific immunoglobulin G in saliva. *J. clin. Microbiol.*, **35**: 98-101, 1997.
16. PARRY, J.V. - Simple and reliable salivary test for HIV and hepatitis A and B virus diagnosis and surveillance. *Ann. N. Y. Acad. Sci.*, **694**: 216-233, 1993.
17. PARRY, J.V.; PERRY, K.R. & MORTIMER, P.P. - Sensitive assays for viral antibodies in saliva: an alternative to tests on serum. *Lancet*, **2**: 72-75, 1987.
18. PARRY, J.V.; PERRY, K.R.; PANDAY, S. & MORTIMER, P.P. - Diagnosis of hepatitis A and B by testing saliva. *J. med. Virol.*, **28**: 255-260, 1989.
19. PIACENTINI, S.C.; THIEME, T.R.; BELLER, M. & DAVIDSON, S.L. - Diagnosis of hepatitis A, B, and C using oral samples. *Ann. N. Y. Acad. Sci.*, **694**: 334-336, 1993.
20. PINHO, J.R.R.; SUMITA, L.M.; MOREIRA, R.C. *et al.* - Duality of patterns in hepatitis A epidemiology: a study involving two socioeconomically distinct populations in Campinas, São Paulo State, Brazil. *Rev. Inst. Med. trop. S. Paulo*, **40**: 105-106, 1998.
21. ROSS, B.C.; ANDERSON, D.A. & GUST, I.D. - Hepatitis A virus and hepatitis A infection. *Advanc. Virus Res.*, **39**: 209-253, 1991.
22. STAPLETON, J.T. - Host immune response to hepatitis A virus. *J. infect. Dis.*, **171**(suppl.1): S9-S14, 1995.
23. STAPLETON, J.T.; LANGE, D.K.; LeDUC, J.W. *et al.* - The role of secretory immunity in hepatitis A virus infection. *J. infect. Dis.*, **163**: 7-11, 1991.
24. THIEME, T.; YOSHIHARA, P.; PIACENTINI, S. & BELLER, M. - Clinical evaluation of oral fluid samples for diagnosis of viral hepatitis. *J. clin. Microbiol.*, **30**: 1076-1079, 1992.
25. ZACHOVAL, R. & DEINHARDT, F. - Hepatitis A virus: natural history and experimental models. In: ZUCKERMAN, A.J. & THOMAS, H., ed. **Viral hepatitis: scientific basis and clinical management**. 2. ed. London, Churchill Livingstone, 1998. p. 43-58.

Received: 03 February 2000

Accepted: 29 March 2000